Effects of Traditional Chinese Patent Medicine on Essential Hypertension: A Systematic Review

Citation

Published Version
doi:10.1097/MD.0000000000000442

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:23473857

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Effects of Traditional Chinese Patent Medicine on Essential Hypertension

A Systematic Review

Xingjiang Xiong, MD, Pengqian Wang, MD, Yuqing Zhang, MD, and Xiaoke Li, MD

Abstract: Traditional Chinese patent medicine (TCPM) is widely used for essential hypertension (EH) in China. However, there is no critically appraised evidence, such as systematic reviews or meta-analyses, regarding the potential benefits and disadvantages of TCPM to justify their clinical use and recommendation. The aim of this review was to systematically evaluate and meta-analyze the effects of TCPM for EH.

Seven databases, the Cochrane Library, PubMed, EMBASE, the China National Knowledge Infrastructure, the Chinese Scientific Journal Database, the Chinese Biomedical Literature Database, and the Wanfang Database, were searched from their inception to August 2014 for relevant studies that compared one TCPM plus antihypertensive drugs vs antihypertensive drugs alone. The methodological quality of the included trials was assessed using the Cochrane risk-of-bias tool. The primary outcome measures were mortality or progression to severe complications and adverse events. The secondary outcome measures were blood pressure (BP) and quality of life (QOL).

Seventy-three trials, which included 8138 patients, on 17 TCPMs were included. In general, the methodological quality was low. Two trials evaluated the effects of TCPMs on mortality and the progression to severe complications after treatment, and no significant difference was identified compared with antihypertensive drugs alone. No severe adverse events were reported. Thirteen TCPMs used in complementary therapy significantly decreased systolic BP by 3.94 to 13.50 mmHg and diastolic BP by 2.28 to 11.25 mmHg. QOL was significantly improved by TCPM plus antihypertensive drugs compared with antihypertensive drugs alone.

This systematic review provided the first classification of clinical evidence for the effectiveness of TCPM for EH. The usage of TCPMs for EH was supported by evidence of class level III. As a result of the methodological drawbacks of the included studies, more rigorously designed randomized controlled trials that focus on mortality and cardiovascular events during long-term follow-up are warranted before TCPM can be recommended for hypertensive patients. Two TCPMs, Song ling xue mai kang capsules and Yang xue qing nao granules, should be prioritized for further research.

(Medicine 94(5):e442)

Abbreviations: AEs = adverse events, BP = blood pressure, CAM = complementary and alternative medicine, CCT = controlled clinical trials, CFDA = China Food and Drug Administration, CI = confidence interval, CNED = Chinese National Essential Drug, CVDs = cardiovascular diseases, DBP = diastolic blood pressure, EH = essential hypertension, PPRA = Pharmacopoeia of the People’s Republic of China, QOL = quality of life, RCT = randomized controlled trial, RR = risk ratio, SBP = systolic blood pressure, TCM = traditional Chinese medicine, TCPM = traditional Chinese patent medicine, TPAD = traditional Chinese patent medicine plus antihypertensive drugs, WMD = weighted mean difference.

INTRODUCTION

Hypertension is one of the most important worldwide public-health challenges because of its high frequency and comitant risks of cardiovascular and kidney disease.1,2 Across all World Health Organization regions, approximately 62% of strokes and 49% of myocardial infarctions are caused by high blood pressure (BP).3 Hypertension has been identified as the fourth leading cause of the global burden of disease.4 The prevention and effective treatment of essential hypertension (EH) is of utmost importance both in China and the West.5 However, the effective control of hypertension is far from satisfactory and is limited by the availability, cost, and adverse effects of antihypertensive medications.1 Therefore, a certain proportion of patients have turned to complementary and alternative medicine (CAM), including traditional Chinese medicine (TCM), in the search for a treatment modality with potential efficacy and few adverse effects. In Western countries, interest in TCM stems from the hope that it might complement Western medicine. This situation is also partially supported by recent studies.6

The most significant distinction between China and the West in EH treatment is the application of acupuncture and traditional Chinese patent medicines (TCPMs), which have been considered complementary or adjunctive therapies for symptom management and quality of life (QOL) enhancement along with mainstream care.7–9 Although no TCPMs have been listed as an investigational new drug by the US Food and Drug Administration, all TCPMs have resulted in great economic and

Editor: Dingchang Zheng.
Received: August 29, 2014; revised: November 5, 2014; accepted: December 15, 2014.
From the Department of Cardiology, Guang'anmen Hospital (XX); Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China (PW); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (YZ); and Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA (XL).
Correspondence: Xingjiang Xiong, MD, Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing 100053, China (e-mail: xiongxingjiangctm@163.com or 5administration@163.com).
The study was financially supported by the National Natural Science Foundation Project of China (No. 81403375).
Author contribution: XJX conceived the idea, set the objectives, and contributed to design and interpretation. PQW, XKL, and YQZ ran the searches, and assessed the methodological quality. XJX made the analysis, having full access to all of the data in the study and taking responsibility for the integrity of the data and the accuracy of the data analysis. XJX and PQW wrote the manuscript. All authors approved the final version of the manuscript.
The authors have no conflicts of interest to disclose.
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000000442
clinical benefits in China. For example, xue qing nao granules are composed of Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Chinese Angelica Root (Danggui, Radix Angelicae Sinensis), Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis), Mother of Pearl (Zhennzhumu, Concha Margaritiferae), Foetid Cassia Seeds (Juemingzi, Semen Cassiae Torae), Prunella (Xiakucuo, Spica Prunellae Vulgares), White Peony Root (Baihsiao, Radix Albus Paeoniae Lactiflorae), Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong), Spatholobus (Jixueng, Cau- lis Milletiae Seu Spatholobi), Corydalis Rhizome (Yanhusuo, Corydalis Rhizome), and Chinese Wild Ginger (Xixin, Herba Asari Cum Radice). Xue qing nao granules have been extensively tested in various types of clinical trials. In 2012, the global market of yang xue qing nao granules was approximately 0.5 billion RMB (equivalent to 81.7 million USD). Several randomized controlled trials (RCTs) and systematic reviews regarding the efficacy of acupuncture for EH have been published in English.10–12 However, there is insufficient clinical evidence to support or discourage the use of many commonly used TCPMs in hypertensive patients,13–14 especially in conjunction with conventional therapy, despite wide acceptance and authoritative recommendations by the China Food and Drug Administration (CFDA) (available at http://www.sda.gov.cn) and the Pharmacopoeia of the People’s Republic of China (2010 edition) for EH in China.15 Therefore, confirmation of the effectiveness of TCPMs as complementary therapies could have a substantial impact on EH management worldwide.

These TCPMs are composed of >100 herbs, most of which have specific antihypertensive effects both in vitro and in vivo when tested alone. Pharmacological studies have indicated that most studied TCPMs can be used to lower BP, and the potential mechanisms may be related to improvements in the plasma levels of endothelin, calcitonin gene-related peptide, and nitric oxide; the inhibition of sympathetic activity; and the regulation of the renin-angiotensin system.16–19 The most commonly used formulations of TCPM for EH include tablets, capsules, pills, granules, and oral liquid. It remains unknown whether there is robust evidence on the clinical effects of TCPM or whether TCPM can be recommended for routine treatment. However, some relevant trials have been reported in China. Thus, the objective of this study was to provide a comprehensive systematic review to summarize and evaluate the evidence regarding the efficacy of TCPM combined with antihypertensive drugs as a complementary therapy for hypertension. To our knowledge, this is the first systematic English-language review of the clinical trials of all TCPMs for the treatment of EH.

METHODS

A methodological evaluation and meta-analysis were conducted in accordance with the recommendations of the Cochrane Collaboration.

Eligibility Criteria

Type of Studies

Only RCTs were eligible for this review, with no restriction on language or publication status. According to the methodological quality of the included RCTs, they were categorized into 3 levels: trials with a clear method of randomization were defined as definite RCTs; trials with an unknown methodology, in which the claimed “RCTs” may not be real “RCTs,” were defined as potential RCTs; and trials that included treatment and control groups, and in which treatment allocation was not necessarily randomized, were defined as controlled clinical trials (CCTs).

Types of Participants

Participants enrolled in the studies of this review had to meet at least one of the current or past guidelines or definitions of EH, which are described as follows: systolic BP (SBP) ≥140 mmHg and/or diastolic BP (DBP) ≥90 mmHg on at least 2 occasions with off-antihypertensive treatment (after a 4-week washout period) and/or treatment with antihypertensive medication, while excluding secondary hypertension. Trials without a description of the detailed diagnostic criteria but that included patients with definite EH were also included. Because there are many TCM syndromes (also known as zheng or patterns) of EH,7,8,9,13,14 no restriction regarding the diagnostic criteria of TCM was utilized. Trials that included patients of any age, sex, or ethnic origin with EH were eligible. There were no restrictions on population characteristics.

Types of Interventions

TCPMs that had been subjected to a relatively strict drug evaluation process, including active constituent identification, a compatibility mechanism study, efficiency and safety evaluation, and RCTs were included. Substantial systemic preclinical or clinical data (regardless of whether they were provided in publications) were available for these selected TCPMs. In our review, only TCPMs listed in the Chinese National Essential Drug (CNED) of 2012 (available at http://www.sda.gov.cn), the Pharmacopoeia of the People’s Republic of China (PPRC) (2010 edition), and commonly used TCPMs in current clinical practice for EH were included in the analysis. Drugs in CNED and PPRC represent the most important therapies listed by the Chinese government, which have been studied extensively and proven to be safe and effective in treatment. More clinical studies reported the use of commonly used TCPMs. In total, 82 TCPMs were identified for further evaluation.

All parallel RCTs of the 82 TCPMs that compared 1 TCPM plus antihypertensive drugs (TPAD) versus antihypertensive drugs alone for EH were eligible. Co-interventions were matched in both the treatment and control groups. Trials were excluded for the following reasons: a multimodal intervention, including TCPM and other complementary and alternative approaches, was used in either the treatment or control groups; a combination of ≥2 TCPMs was included in the treatment group; head-to-head comparisons of different types of TCPMs were utilized without a standard Western medicine control group; the types and dosages of antihypertensive drugs used in the treatment or control groups were not the same; only biochemical markers, rather than BP, were reported; no data on BP outcome could be extracted; and duplicated publications reported the same results. Trials that evaluated any TCPM formulation (tablets, capsules, or pills) were included regardless of the treatment period length and the treatment dosage.

Types of Outcome Measures

For inclusion, RCTs had to have evaluated at least one of the following outcomes. The primary outcome measures included mortality, progression to severe complications, and adverse events (AEs). Severe complications were defined as coronary heart disease, myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage, transient ischemic attack, renal failure, and retinopathy. The secondary outcome...
measures included SBP, DBP, and QOL after treatment. Trials were excluded if missing information about the outcome measure were found.

**Search Strategy**

Studies on 82 TCMs were identified through searches of the following 7 electronic databases from their inception until August 17th, 2014: the Cochrane Library (searched in August 2014), PubMed (1959–2014), EMBASE (1980–2014), the China National Knowledge Infrastructure (1979–2014), the Chinese Scientific Journal Database (1989–2014), the Chinese Biomedical Literature Database (1978–2014), and the Wanfang Database (1985–2014). Because TCMs were invented and are primarily used in China, we conducted a literature search in the 4 main Chinese electronic databases to include the maximum possible number of clinical trials. To include unpublished studies, we also searched the website of the Chinese clinical trial registry (available at http://www.chictr.org/) and the international clinical trial registry maintained by the US National Institutes of Health (available at http://clinicaltrials.gov/).

For the database searches, the following keywords were used in combination: (“clinical trial” OR “randomized trial” OR “randomized controlled trial” OR “randomised controlled trial”) AND (“essential hypertension” OR “primary hypertension” OR “high blood pressure” OR “blood pressure”) AND (“traditional Chinese patent medicine” OR “Chinese patent medicine” OR “song ling xue mai kang capsule” OR “Pinus armandi Franch benefitting blood vessel capsule” OR “yang xue ning tablet” OR “huffishing the blood and clearing brain granule” OR “luo mai kang capsule” OR “tian shu capsule” OR “calming heart antihypertensive syrupus” OR “gao xue ya su jiang pill” OR “quickly lowering blood pressure pill” OR “xue ya an ba bu gao” OR “antihypertensive babu plaster” OR “jiu qiang nai ling tablet” OR “ enduring and powerful clearing brain pill” OR “luobuma tea” OR “apocynum tea” OR “luobumaye granule” OR “apocynum venetum leaves granule” OR “sanqihua granule” OR “notoginseng flower granule” OR “xin ling pill” OR “calming heart pill” OR “dong qing bu zhi” OR “holly fill juice” OR “duzhong granule” OR “eucommia granule” OR “feng shi xi tong tablet” OR “siesbeckiae and clerodendroa trichotomum tablet” OR “shanzha jing jian tablet” OR “hawthorn lipid-lowering tablet” OR “qu xue ya su jiang pill” OR “calming heart and blood tablet” OR “promoting heart and blood circulation tablet” OR “shanzha jing ling tablet” OR “hawthorn lipid-lowering tablet” OR “duzhong ping ya capsule” OR “eucommia antihypertensive tablet” OR “shanzha jing zhi tablet”).

In addition, to include studies primarily used in China, we conducted a literature search in the Chinese Scientific Journal Database (1989–2014), the China National Knowledge Infrastructure (1979–2014), PubMed (1959–2014), EMBASE (1980–2014), the Chinese national clinical trial registry maintained by the US National Institutes of Health (available at http://www.chictr.org/) and the international clinical trial registry (available at http://clinicaltrials.gov/). For the database searches, the following keywords were used in combination: (“clinical trial” OR “randomized trial” OR “randomized controlled trial” OR “randomised controlled trial”) AND (“essential hypertension” OR “primary hypertension” OR “high blood pressure” OR “blood pressure”) AND (“traditional Chinese patent medicine” OR “Chinese patent medicine” OR “song ling xue mai kang capsule” OR “Pinus armandi Franch benefitting blood vessel capsule” OR “yang xue ning tablet” OR “huffishing the blood and clearing brain granule” OR “luo mai kang capsule” OR “tian shu capsule” OR “calming heart antihypertensive syrupus” OR “gao xue ya su jiang pill” OR “quickly lowering blood pressure pill” OR “xue ya an ba bu gao” OR “antihypertensive babu plaster” OR “jiu qiang nai ling tablet” OR “ enduring and powerful clearing brain pill” OR “luobuma tea” OR “apocynum tea” OR “luobumaye granule” OR “apocynum venetum leaves granule” OR “sanqihua granule” OR “notoginseng flower granule” OR “xin ling pill” OR “calming heart pill” OR “dong qing bu zhi” OR “holly fill juice” OR “duzhong granule” OR “eucommia granule” OR “feng shi xi tong tablet” OR “siesbeckiae and clerodendroa trichotomum tablet” OR “shanzha jing jian tablet” OR “hawthorn lipid-lowering tablet” OR “qu xue ya su jiang pill” OR “calming heart and blood tablet” OR “promoting heart and blood circulation tablet” OR “shanzha jing ling tablet” OR “hawthorn lipid-lowering tablet” OR “duzhong ping ya capsule” OR “eucommia antihypertensive tablet” OR “shanzha jing zhi tablet”).
Data Extraction and Management
Two reviewers independently screened the trials based on the titles and abstracts. The following information was extracted from the eligible trials that met the inclusion criteria: basic characteristics (age, gender, race of participants, and sample size) of the included subjects and basic characteristics (authors, title of study, year of publication, randomization, allocation concealment, blinding, intention to treat analysis, drop-out or withdrawal, diagnosis standard, TCPM name, interventions in the treatment and control groups, outcome measures, treatment duration, and safety reporting) of the included trials. Missing data were obtained from the original authors via email, fax, or telephone when possible. Disagreements were resolved by discussion with a third reviewer.

Data Analysis
Data regarding outcomes in the eligible studies were combined in the meta-analysis using the Revman 5.1 software provided by the Cochrane Collaboration. Dichotomous data were presented as the risk ratio (RR), and continuous outcomes were presented as the weighted mean difference (WMD); both measurements were reported with the 95% confidence interval (CI). Statistical heterogeneity between the studies was significant when $I^2 \geq 50\%$. Fixed-effects model was used if there was no significant heterogeneity of the data ($I^2 < 50\%$); random-effects model was used if significant heterogeneity existed. The risk of publication bias was assessed by funnel plot analysis for each meta-analysis if sufficient studies (ie, $>10$) were identified.

Risk of Bias in Individual Studies
Two reviewers independently assessed the risk of bias in the included studies using tools from the Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011). The factors assessed included the following 7 items: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting (reporting bias); and other sources of bias (from Chapter 8: assessing risk of bias in included studies). For each item, the risk of bias was classified as “low,” “unclear,” or “high” according to the previously discussed criteria.

RESULTS

Literature Search
Figure 1 shows a flowchart that depicts the study search and selection process. An initial screening yielded 12,004 potentially relevant citations in accordance with the search strategy. A total of 11,886 articles were screened after 118 duplicates of the same articles included in different databases were removed. According to the inclusion criteria, 11,731 articles were excluded on the basis of the titles and abstracts. These studies were primarily excluded because they were not RCTs. After a full text reading of 155 studies, 82 articles were excluded for the following reasons: the participants did not meet the inclusion criteria (n = 70), duplication (n = 2), no control group (n = 3), intervention included other Chinese herbal formula (n = 5), no data for extraction (n = 2).
group (n = 3), the intervention included another Chinese herbal formula (n = 5), and no data for extraction (n = 2). Ultimately, 73 studies were included for analysis.21–93

Study Characteristics

The characteristics of the 73 included trials are summarized in Table 1. Of the 82 TCPMs, definite or possible RCTs and CCTs for 17 TCPMs were identified. For the remaining 67 TCPMs, we only identified case reports, case series, and uncontrolled observational studies. Seventy-three trials regarding 17 TCPMs were included, of which 63 and 10 trials were definite or possible RCTs and CCTs, respectively. All trials were conducted in China and published in Chinese journals (from 1994 to 2013).

The RCTs included 8138 participants with EH. The age of the hypertensive patients ranged from 23 to 88 years. Standard Western medicine diagnostic criteria for EH was applied in all included trials. Additionally, many trials used TCM diagnostic criteria according to TCM theory. The formulations of the TCPMs included capsules, granules, pills, oral liquid, and tablets. Components of the 17 included TCPMs were depicted in Table 2.21–93 All 73 trials were single-center trials and had parallel designs that compared TPAD in a treatment group versus antihypertensive drugs in a control group. The patients in the treatment group were treated with the same type and dosage of antihypertensive drugs under the same standard in the control group. The total treatment duration ranged from 2 weeks to 1 year.

Two trials reported mortality and progression to severe complications after a 1-year follow-up.46,66 BP was assessed in all included trials. The treatment durations of 5 trials was >6 months.42,46,50,66,69 The QOL was reported in 5 trials,33,36,42,76,92 of which 4 trials33,36,42,76 used the Croog Scale.94 and 1 trial92 used the SF-36 Scale.95 The AEs of 33 trials have been described in detail.

Risk of Bias in Individual Studies

The risk of bias in the included trials was assessed as unclear and high according to the predefined Cochrane criteria. No randomized, double-blind, and placebo-controlled trial was identified. Only 4 trials on Song ling xue mai kang capsules,21,23,28,44 1 trial on Yang xue qing nao granules,51 1 trial on Liu wei dihuang pills,65 2 trials on Xin ke shu,70,71 2 trials on Tianma gouteng granules,76,77 1 trial on Quan tianma capsules,91 1 trial on Zhen jiu xue mai tablets,87 and 1 trial on Qi xue qing nao capsules.89

The remaining 50 trials simply declared that patients with EH were randomized into treatment and control groups without a description of the specific method. No detailed information was provided to judge whether the study was conducted properly. One trial reported the blinding of participants and personnel.28 Allocation concealment and the blinding of the outcome assessment were not mentioned in all included trials. Six trials reported drop-outs or withdrawals.21,37,46,56,60,79 A pre-trial estimation of sample size was not reported in all trials. We attempted to contact the corresponding authors via telephone, fax, and email for inadequate information; however, most studies did not provide detailed contact information, and no additional information could be obtained to date.

Primary Outcomes

Mortality and Progression to Severe Complications

The effects of TCPM on mortality and the progression to severe complications were only reported in 2 trials.46,66 One trial on Yang xue qing nao granules (130 patients) assessed the incidence of mortality and progression to severe complications at 1 year after treatment compared with antihypertensive drugs (with no detailed information regarding the classification or dosage).66 No deaths or severe complications occurred in the Yang xue qing nao granules group. However, 5 cases of coronary heart disease and 2 cases of transient ischemic attack were identified in the antihypertensive drugs group. A meta-analysis indicated that there was no significant difference between Yang xue qing nao granules and antihypertensive drugs regarding the incidence of coronary heart disease (RR: 0.09; 95% CI: 0.00–1.60; P = 0.10) or a transient ischemic attack (RR: 0.20; 95% CI: 0.01–4.25; P = 0.30).

Another trial also evaluated the effects of quan tianma capsules (500 patients) on the incidence of mortality and the progression to severe complications compared with nifedipine sustained-release tablets (10 mg, bid).66 The meta-analysis indicated that there was no significant difference between quan tianma capsules and nifedipine sustained-release tablets for the incidence of coronary heart disease (RR: 0.84; 95% CI: 0.54–1.29; P = 0.43), myocardial infarction (RR: 0.57; 95% CI: 0.24–1.36; P = 0.21), heart failure (RR: 0.42; 95% CI: 0.11–1.57; P = 0.20), cerebral infarction (RR: 1.04; 95% CI: 0.66–1.62; P = 0.87), cerebral hemorrhage (RR: 0.43; 95% CI: 0.13–1.44; P = 0.17), transient ischemic attack (RR: 1.15; 95% CI: 0.76–1.72; P = 0.51), renal failure (RR: 0.91; 95% CI: 0.42–1.96; P = 0.81), retinopathy (RR: 1.06; 95% CI: 0.49–2.32; P = 0.88), or death (RR: 0.26; 95% CI: 0.06–1.04; P = 0.06).

AEs

AE monitoring was reported in 33 trials on 13 TCPMs.21–23,28–30,33,35,38–40,43,45–50,53,60,68,71,74,77,79,84,85,88–91 whereas it is not mentioned in the remaining 40 trials. The 13 included TCPMs were Liu wei dihuang pills, Niuhuang jiang ya pills, Qian li ding xuan tablets, Qian li tianma duzhong capsules, Quan tianma capsules, Song ling xue mai kang capsules, Tianma gouteng granules, Tianma shouwu tablets, Xin ke shu, and Yang xue qing nao granules. Of the 33 trials, no AEs were reported in 10 trials and with Quan xing qiao ya tablets. The AEs of the other 12 TCPMs included orthostatic hypotension, headache, dizziness, facial flushing, palpitations, nasal congestion, drowsiness, rash, pruritus, dry mouth, cough, nausea, abdominal discomfort, diarrhea, constipation, and ankle edema. No serious AEs were identified, and all AEs disappeared without special treatment. There were 1087 patients in the TPAD group and 1083 patients in the antihypertensive drugs group. Because significant heterogeneity among the trials on every TCPM existed (chi-square = 28.21, P = 0.003; F = 61%), a random-effects model was applied. A meta-analysis of all 12 TCPMs indicated that there was no significant difference regarding the AEs between TPAD and antihypertensive drugs (RR: 0.57; 95% CI: 0.32–1.00; P = 0.05), with the exception of Xin ke shu (RR: 0.11; 95% CI: 0.04–0.29; P < 0.0001). Yang xue qing nao granules (RR: 0.18; 95% CI: 0.05–0.60; P = 0.005), and Qing nao jiang ya tablets (RR: 22.05; 95% CI: 1.34–363.98; P = 0.03) (Figure 2).
<table>
<thead>
<tr>
<th>Drug</th>
<th>RCT</th>
<th>CCT</th>
<th>Outcome Measures</th>
<th>No. of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Definite, Double-blind, Placebo, Method clear</td>
<td>Definite, Method Clear</td>
<td>Possible, method unclear</td>
<td>Quasi-RCT (Sequence of Admission)</td>
</tr>
<tr>
<td>17 TCPMs with eligible clinical trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Song ling xue mai kang capsules</td>
<td>0</td>
<td>4</td>
<td>15</td>
<td>4</td>
</tr>
<tr>
<td>Yang xue qing nao granules</td>
<td>0</td>
<td>1</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Liu wei dihuang pills</td>
<td>0</td>
<td>1</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Quan tianma capsules</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Xin ke shu</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Qing nao jiang ya tablets</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Tianma gouteng granules</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Qiang li tianma duizhong capsules</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Qi ju dihuang pills</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Niuhuang jiang ya pills</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Zhen ju jiang ya tablet</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Qiang li ding xuan tablet</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tianma shouwu tablet</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Qing gan jiang ya capsules</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Qing xuan jiang ya tablet</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tian shu capsules</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Comu saigae tataricae capsules</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>63</td>
<td>10</td>
<td>2</td>
<td>73</td>
</tr>
</tbody>
</table>
Secondary Outcomes

BP

All 73 included trials evaluated the effects of TCPMs on BP in individuals with EH. Fourteen trials used the categorical BP to evaluate the efficacy of 8 TCPMs, the evaluation criteria of which were authoritatively recommended by the CFDA and the Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine. The effects were described as follows: ‘‘significant improvement’’ (DBP decreased by 10 mmHg and reached the normal range or DBP did not return to normal but decreased by more than 20 mmHg), ‘‘improvement’’ (DBP decreased by <10 mmHg but reached the normal range, DBP decreased by 10–19 mmHg but did not reach the normal range, or SBP decreased by >30 mmHg), and ‘‘no improvement’’ (did not meet the previously discussed standards). To permit at least some overall analysis, these outcomes were converted into dichotomous data. Therefore, we grouped together ‘‘significant improvement’’ and ‘‘improvement’’ as ‘‘effective’’ and ‘‘no improvement’’ as ‘‘ineffective.’’ The 8 TCPMs that were included were Liu wei dihuang pills, Niuhuang jiang ya pills, Qi ju dihuang pills, Quan tianma capsules, Song ling xue mai kang capsules, Tianma gouteng granules, Tianma shouwu tablets, and Yang xue qing nao granules. There were 809 patients in the TPAD group and 787 individuals in the antihypertensive drugs group. Fixed-effects model was used because no significant heterogeneity of the trials was identified (chi-square = 5.29, \( P = 0.62 \); \( I^2 = 0 \%)\). A meta-analysis of the 14 trials on the 8 TCPMs identified a significant BP-lowering effect of TPAD (RR: 1.15; 95% CI: 1.10–1.20; \( P < 0.00001 \)) compared with antihypertensive drugs alone (Figure 3).

Fifty-nine trials used continuous BP to evaluate the treatment effects of 16 TCPMs in hypertensive patients, with the exception of Tianma shouwu tablets. The combined results suggested that 13 TCPMs (13/16, 81.25%) used as complementary therapy to antihypertensive drugs significantly decreased SBP by 3.94–13.50 mmHg; however, the other 3 TCPMs (3/16, 18.75%) decreased SBP by 1.00–5.00 mmHg, with no significant difference compared with antihypertensive drugs alone. The meta-analysis also indicated that 9 TCPMs (9/16, 56.25%) used as complementary therapy to antihypertensive drugs significantly decreased DBP by 2.28–11.25 mmHg; however, the other 7 TCPMs (7/16, 43.75%) decreased DBP by -1.00–9.41 mmHg with no significant difference compared with antihypertensive drugs alone. The detailed effect sizes of TPAD compared with antihypertensive drugs are summarized in Table 3. Two TCPMs, Song ling xue mai kang capsules (854 vs 835) and Yang xue qing nao granules (882 vs. 879), had more studies and >1000 patients, respectively.

Quality of Life

Both the Croog and SF-36 scales were used to assess the QOL in 5 trials regarding Song ling xue mai kang capsules,33,36,42 Tianma gouteng granules,76 and Tian shu capsules.92 All 5 trials reported a significant improvement in the QOL of the TPAD group compared with the antihypertensive drug group at the end of treatment. One trial on Song ling xue mai kang capsules33 demonstrated that the Croog Scale increased with the total score (WMD = 26.10; 95% CI: 25.88–26.32; \( P < 0.00001 \)). The other 2 trials on song ling xue mai kang capsules6,42 all reported a significant improvement in the sense of wellbeing (WMD = 7.70; 95% CI: 7.54–7.87; \( P < 0.00001 \)), physical symptoms (WMD = 2.56; 95% CI: 2.28–2.84;
<table>
<thead>
<tr>
<th>TCPMs</th>
<th>Components</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Song ling xue mai kang capsules</td>
<td>Fresh Pine Needles (Xiansongye, Pinus armandi Franch), Pueraria (Gegen, Radix Puerariae), and Pearl (Zhenzhu, Margarita)</td>
<td>21–44</td>
</tr>
<tr>
<td>Yang xue qing niao granules</td>
<td>Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Chinese Angelica Root (Danggui, Radix Angelicae Sinensis), Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis), Mother of Pearl (Zhenzhumu, Concha Margaritaeferae), Foetid Cassia Seeds (Jueyingzi, Semen Cassiae Torae), Prunella (Xiaokucao, Spica Prunellae Vulgaris), White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae), Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chaunxiang), Spatholobus (Jinxut, Caulis Spatholobi), Corydalis Rhizome (Yanhusuo, Corydalis Rhizome), and Chinese Wild Ginger (Xixin, Herba Asari Cum Radice)</td>
<td>45–54</td>
</tr>
<tr>
<td>Liu wei dihuang pills</td>
<td>Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Cornus Fruit (Shanzhuyu, Corni Fructus), Dioscorea Root (Shanyao, Dioscoreae Rhizoma), Poria (Fuling, Scierotium Poriae Cocos), Alisma (Zexie, Rhizoma Alismatis), and Cortex of the Peony Tree Rote (Danpi, Cortex Radicis Moutan)</td>
<td>55–65</td>
</tr>
<tr>
<td>Quan tianma capsules</td>
<td>Gastrodia (Tianma, Gastrodiae Rhizoma), Salvia Root (Danshen, Radix Salviae Miltiorrhizae), Pueraria (Gegen, Radix Puerariae), Notoginseng Root (Sanqi, Notoginseng Radix), Craetaegus Fruit (Shanzha, Craetaegi Fructus), and Costus Root (Muxiang, Radix Aucklandiae Lappae)</td>
<td>66–68</td>
</tr>
<tr>
<td>xin ke shu</td>
<td>Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Prunella (Xiaokucao, Spica Prunellae Vulgaris), Pagoda Tree Flower (Huaimi, Fls Immaturus Sophorae Japonice), Magnetite (Cishi, Magnetitum), Achyranthes Root (Niuixi, Achyranthis Bidentatae Radix), Chinese Angelica Root (Danggu, Radix Angelicae Sinensis), Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Salvia Root (Danshen, Radix Salviae Miltiorrhizae), Leech (Shuizhi, Hirudo seu Whitmania), Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis), Foetid Cassia Seeds (Jueyingzi, Semen Cassiae Torae), Earthworm (Dilong, Lumbricus), and Mother of Pearl (Zhenzhumu, Concha Margaritaeferae)</td>
<td>69–72</td>
</tr>
<tr>
<td>Qing nao jiang ya tablets</td>
<td>Gastrodia (Tianma, Gastrodiae Rhizoma), Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis), Abalone Shell (Shijueming, Haliotidis Concha), Eucommia Bark (Duzhong, Cortex Eucommiae), Achyranthes Root (Niuixi, Achyranthis Bidentatae Radix), Chinese Taxillus Twig (Sangjiseng, Herba Taxilli), Gardenia (Zhizi, Fructus Gardeniae Jasminoidis), Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Chinese Motherwort (Yimucao, Herba Leonuri Heterophylli), Poria (Fuling, Scierotium Poriae Cocos), and Flowey Knotweed Stem (Shouwuteng, Polygoni Multiflori Caulis)</td>
<td>73–75</td>
</tr>
<tr>
<td>Tianna gouteng granules</td>
<td>Gastrodia (Tianma, Gastrodiae Rhizoma), Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis), Achyranthes Root (Niuixi, Achyranthis Bidentatae Radix), Chinese visum herb (Huijisheng, Herba Visci), Ningpo Figwort Root (Xianshen, Radix Scrophulariae Nigrum), Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Chinese Angelica Root (Danggu, Radix Angelicae Sinensis), Processed aconite (Fuzi, Radix Lateralis Praeparatus Carminae), Prepared Wild Aconite (Caowu, Radix Aconiti Kusnezoffii Preparata), Notopterygium Root (Qiexiang, Notopterygii Rhizoma), Paeonia Radix (Dushe, Radix Angelicae Pubescientis), and Straw Weed (Gaoben, Radix Et Rhizoma Ligustici Chinesis)</td>
<td>76–78</td>
</tr>
<tr>
<td>Qiang li tianma duzhong capsules</td>
<td>Gastrodia (Tianma, Gastrodiae Rhizoma), Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis), Achyranthes Root (Niuixi, Achyranthis Bidentatae Radix), Chinese visum herb (Huijisheng, Herba Visci), Ningpo Figwort Root (Xianshen, Radix Scrophulariae Nigrum), Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Chinese Angelica Root (Danggu, Radix Angelicae Sinensis), Processed aconite (Fuzi, Radix Lateralis Praeparatus Carminae), Prepared Wild Aconite (Caowu, Radix Aconiti Kusnezoffii Preparata), Notopterygium Root (Qiexiang, Notopterygii Rhizoma), Paeonia Radix (Dushe, Radix Angelicae Pubescientis), and Straw Weed (Gaoben, Radix Et Rhizoma Ligustici Chinesis)</td>
<td>79–81</td>
</tr>
<tr>
<td>Qi jiu dihuang pills</td>
<td>Chinese Wolfberry Fruit (Gouqizi, Fructus Lycii Chinensis), Chrysanthemum Flower (Juehua, Fls Chrysanthemi Morifolii), Rehmannia (Dihuang, Radix Rehmanniae Glutinosae), Cornus Fruit (Shanzhuyu, Corni Fructus), Dioscorea Root (Shanyao, Dioscoreae Rhizoma), Poria (Fuling, Scierotium Poriae Cocos), Alisma (Zexie, Rhizoma Alismatis), and Cortex of the Peony Tree Rote (Danpi, Cortex Radicis Moutan)</td>
<td>82–83</td>
</tr>
<tr>
<td>niu huang jiang ya pills</td>
<td>extracts from Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Codonopsis Root (Dangshen, Radix Codonopsis Piluloe), Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiang), White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae), Borneol (Bingping, Borneolom), Foetid Cassia Seeds (Jueyingzi, Semen Cassiae Torae), Chinese Nardostachys Rhizome (Gansong, Radix Et Rhizoma Nardostachydis), Tumeric Tuber (Yujin, Tuber Curcumae), Field Mint (Bohe, Herba Menthae Haplocalycis), Cattle (Niu huang, Calculus Bovis), Antelope Horn (Lingyangjiao, Cornu Saigae Tataricae), Buffalo Horn (Shuizhi, Hirudo seu Whitmania), and Pearl (Zhenzhu, Margarita)</td>
<td>84–86</td>
</tr>
<tr>
<td>Zhen ju jiang ya tablets</td>
<td>Wild Chrysanthemum Flower (Yuejia, Fls Chrysanthemi Indici), Pearl (Zhenzhu, Margarita), clonidine hydrochloride, hydrocholorothiazide, and rutin</td>
<td>87</td>
</tr>
<tr>
<td>Qiang li ding xuan tablets</td>
<td>Gastrodia (Tianma, Gastrodiae Rhizoma), Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis), Wild Chrysanthemum Flower (Juehua, Fls Chrysanthemi Indici), leaves of Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis), and Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiang)</td>
<td>88</td>
</tr>
</tbody>
</table>
TCPMs Components Refs

Tianma shouwu tablets Gastodia (Tianma, Gastrodiae Rhizoma), Dahurian Angelica Root (Baizhi, Radix Angelicae Dahuricae), Fleeceflower Root (Heshouwu, Radix Polygomi Multiflori). Rehmannia (Dihuang, Radix Rehmannii Glutinosae), Salvia Root (Dansen, Radix Salviae Miltiorrhiza), Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong), Chinese Angelica Root (Danggui, Radix Angelicae Sinensis), Puncturevine Caltrop Fruit (Cijili, Tribulus terrestris Linn), Mulberry Leaf (Sangye, Mori Folium), Eclipta (Hanliancao, Herba Ecliptae Prostratae), Privet Fruit (Xiaoji, Fructus Ligustri Lucidi), Common Cephalanoplos Herb (Xiaoji, Herba Taxilli), Prunella (Xiakucao, Spica Prunellae Vulgaris), Pagoda Tree Flower (Huaihua, Flos Immaturus Sophorae Japonice), Common Cephalanoplos Herb (Xiaoji, Herba Cirsii), Salvia Root (Dansen, Radix Salviae Miltiorrhiza), Pueraria (Gegen, Radix Puerariae), Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix), Alisma (Zexie, Rhizoma Alismatis), and Chinese Senega Root (Yuanzhi, Radix Polygala Tenuifoliae).

Qing gan jiang ya capsules Fleeceflower Root (Heshouwu, Radix Polygomi Multiflori), Chinese Taxillus Twig (Sangjisheng, Herba Taxilli), Prunella (Xiaikucao, Spica Prunellae Vulgaris), Pagoda Tree Flower (Huaihua, Flos Immaturus Sophorae Japonice), Common Cephalanoplos Herb (Xiaoji, Herba Cirsii), Salvia Root (Dansen, Radix Salviae Miltiorrhiza), Pueraria (Gegen, Radix Puerariae), Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix), Alisma (Zexie, Rhizoma Alismatis), and Chinese Senega Root (Yuanzhi, Radix Polygala Tenuifoliae).

Qing xuan jiang ya tablets Radish Seed (Laifuzi, Semen Raphani Sativi)

tian shu capsules Gastodia (Tianma, Gastrodiae Rhizoma) and Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong)

Cornu saigae tataricae capsules Antelope Horn (Lingyangjiao, Cornu Saigae Tataricae)

TCPM = traditional Chinese patent medicine.

P < 0.00001), work performance and satisfaction (WMD = 2.54; 95% CI: 2.37–2.72; P < 0.00001), and life satisfaction (WMD = 3.48; 95% CI: 3.28–3.68; P < 0.00001) compared with the antihypertensive drug group. One trial on Tianma gouteng granules97 demonstrated a significant improvement on the Croog Scale (WMD = 13.93; 95% CI: 8.10–19.76; P < 0.00001). One trial on tian shu capsules92 exhibited a significant reduction in the total score of the SF-36 Scale (WMD = −27.56; 95% CI: −28.67 to −26.45; P < 0.00001).

DISCUSSION

Summary of Evidence

The previous decade has witnessed an unprecedented expansion of the field of antihypertensive treatment and drug discovery and development. Thus, Western medicine became the dominant medical treatment worldwide. However, it has been increasingly realized that Western medicine may sometimes fail to treat cardiovascular diseases (CVDs), especially in patients with a history of conventional medicine-related AEs, whereas CAM is becoming increasingly popular and frequently used among patients with CVDs.97,98 As a result of the different theoretical systems and control methods, Western physicians often find CAM difficult to understand. TCM has continued to hold an important position in primary healthcare both in China and other Asian countries.99 Additionally, there is one important characteristic of China’s national medical system that facilitates CAM, that is, integrative medicine, which combines TCM and Western medicine together in the clinic and is responsible for health care.100,101 Therefore, as an adjunctive treatment to antihypertensive drugs, TCPM is a popular natural product for EH.102 Because of its health-enhancing qualities, TCPM has been developed and used in China for >30 years. Currently, there are 82 TCPMs approved by the CFDA for the treatment of EH.102

FIGURE 2. Forest plot of the reported AEs with 13 TCPMs. AD = antihypertensive drugs, AEs = adverse events, TCPM = traditional Chinese patent medicine.
treatment of EH. However, few TCPMs have been evaluated regarding their effectiveness and safety according to current scientific standards; furthermore, few relevant articles on TCPMs for EH have been published in English-language medical journals. There is a lack of studies that assess the majority of the commonly used TCPMs for EH, which has limited their clinical use and weakened the credibility of the study of TCPM internationally. In this article, although many TCPMs did not meet our selection criteria, the findings provided the current status of the clinical evidence regarding the approved TCPMs for EH in China. The methodological quality of most included trials was evaluated as generally ‘poor’ because of inadequate reporting of their methods in detail. However, we did not arbitrarily exclude them because we sought to report on the overall quality. As the first systematic review, this study aimed to assess the quantity, quality, and overall strength of the evidence regarding the most commonly used and government-recommended TCPMs for EH.

There are several strengths in this study. Previous studies have demonstrated that antihypertensive medicine treatment is associated with a substantial reduction of cardiovascular events and mortality. There is the possibility that TCPM could, as a complementary therapy to antihypertensive drugs, more significantly lower the incidence rate of major cardiovascular events. In this review, the first finding was the evidence regarding the efficacy of the evaluated TCPMs on primary outcomes. There was inadequate reporting of primary outcome measures. Only 2 trials on Yang xue qing nao granules and Quan tianma capsules assessed the long-term outcomes of mortality and progression to severe complications after treatment. No significant difference between the treatment and control groups was identified. Therefore, no convincing evidence of the beneficial effects that support the routine use of TCPM as an adjunctive therapy for EH could be drawn because of the very limited numbers of RCTs and the patients in these 2 trials. Nonetheless, the findings demonstrated that long-term outcomes of TCPM could be evaluated with RCTs.

Another valuable finding of this review was the estimation of the incidence of AEs. There was a lack of knowledge regarding the significance of reporting the frequency of AEs in the RCTs. TCPM appeared to be free of major AEs. The reported AEs were not severe and required no additional special treatment. Although the aggregated results indicated that there was no difference regarding the AEs between the 2 groups, the safety of TCPMs must still be rigorously monitored and appropriately reported in future clinical trials.

The most striking finding in this systematic review was the estimation of the therapeutic effects of TCPM on secondary outcomes. We also evaluated the effectiveness of TCPM in lowering BP in individuals with EH. The BP outcomes were reported in all included trials. The meta-analysis indicated that 13 TCPMs (81.25%) possess a better BP-lowering effect as complementary therapies, with a SBP decrease of 3.94 to 13.50 mmHg and a DBP decrease of 2.28 to 11.25 mmHg. For example, a significant BP-lowering effect of the most commonly used 2 TCPMs, song Ling xue mai kang capsules (SBP decreased by 7.30 mmHg and DBP decreased by 6.74 mmHg) and Yang xue qing nao granules (SBP decreased by 8.11 mmHg and DBP decreased by 4.91 mmHg), was identified. However, confirmation regarding BP was limited because of the poor methodological quality, the lack of placebo-controlled trials, and the significant heterogeneity of the included trials (Figure 4). Therefore, more evidence is required to confirm these conclusions. If the beneficial effects on BP were confirmed by rigorously designed trials with high methodological quality, it could lead to the identification and use of many valuable treatments for EH.

The fourth finding was the evaluation of the effects of TCPM on QOL. In this review, the data regarding QOL were insufficient. Only 5 trials on 3 TCPMs (Song Ling xue mai kang capsules, Tianma gouteng granules, and Tian shu capsules) assessed the QOL in hypertensive patients using the Croog and SF-36 scales. Although the QOL in the treatment groups was generally higher than in the control groups for 3 TCPMs, more rigorously designed RCTs are warranted to confirm these results.

LIMITATIONS

Our study has several limitations. First, all included trials were of poor methodological quality. In our review, in fact, it was impossible to identify well-designed trials to evaluate the efficacy of TCPM for the management of EH. All the included trials were shown to have a high or unclear risk of bias due to design, reporting, and methodology. Inadequate reports of the study design, allocation sequence, allocation concealment, blinding, intention-to-treat analysis, and drop outs were identified in the majority of the trials. There were no definite randomized, double-blind, placebo-controlled trials with clear

![TABLE 3](https://example.com/table3.png)

**FIGURE 3.** Forest plot of the trials that compared TPAD with antihypertensive drugs for BP. AD = antihypertensive drugs, BP = blood pressure, TPAD = traditional Chinese patent medicine plus antihypertensive drugs.
TABLE 3. Effect sizes of TPAD Compared with Antihypertensive Drugs

<table>
<thead>
<tr>
<th>TCPM</th>
<th>No. of Studies</th>
<th>No. of Participants</th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Song ling xue mai kang capsules</td>
<td>19</td>
<td>1689</td>
<td>WMD: −7.30 (−8.56, −6.04); P &lt; 0.000001</td>
<td>WMD: −6.74 (−8.32, −5.16); P &lt; 0.000001</td>
</tr>
<tr>
<td>Yang xue qing nao granules</td>
<td>8</td>
<td>1761</td>
<td>WMD: −8.11 (−11.96, −4.27); P &lt; 0.000001</td>
<td>WMD: −4.91 (−7.42, −2.40); P &lt; 0.000001</td>
</tr>
<tr>
<td>Liu wei dihuang pills</td>
<td>9</td>
<td>833</td>
<td>WMD: −7.76 (−10.01, −5.50); P &lt; 0.000001</td>
<td>WMD: −6.61 (−7.60, −5.62); P &lt; 0.000001</td>
</tr>
<tr>
<td>Quan tianma capsules</td>
<td>2</td>
<td>600</td>
<td>WMD: −3.94 (−5.21, −2.68); P &lt; 0.000001</td>
<td>WMD: −3.89 (−4.90, −2.87); P &lt; 0.000001</td>
</tr>
<tr>
<td>Xin ke shu</td>
<td>4</td>
<td>371</td>
<td>WMD: −8.68 (−15.35, −2.02); P = 0.01</td>
<td>WMD: −1.96 (−5.12, 1.21); P = 0.23</td>
</tr>
<tr>
<td>Qing naco jiang ya tablets</td>
<td>3</td>
<td>324</td>
<td>WMD: −7.19 (−8.86, −5.52); P &lt; 0.000001</td>
<td>WMD: −9.41 (−21.07, 2.25); P = 0.11</td>
</tr>
<tr>
<td>Tianma gouteng granules</td>
<td>2</td>
<td>157</td>
<td>WMD: −4.91 (−7.23, −2.60); P &lt; 0.0001</td>
<td>WMD: −2.92 (−7.81, 1.98); P = 0.24</td>
</tr>
<tr>
<td>Qiang li tianma duzhong capsules</td>
<td>3</td>
<td>214</td>
<td>WMD: −2.34 (−4.91, 0.23); P = 0.07</td>
<td>WMD: −2.28 (−3.96, −0.60); P = 0.008</td>
</tr>
<tr>
<td>Qi ju dihuang pills</td>
<td>1</td>
<td>80</td>
<td>WMD: −5.00 (−20.44, 10.44); P = 0.53</td>
<td>WMD: −1.00 (−3.23, 1.23); P = 0.38</td>
</tr>
<tr>
<td>Niuhuang jiang ya pills</td>
<td>2</td>
<td>130</td>
<td>WMD: −7.13 (−10.17, −4.09); P &lt; 0.000001</td>
<td>WMD: −6.61 (−13.47, 0.25); P = 0.06</td>
</tr>
<tr>
<td>Zhen ju jiang ya tablets</td>
<td>1</td>
<td>150</td>
<td>WMD: −6.68 (−9.02, −4.34); P &lt; 0.000001</td>
<td>WMD: −5.94 (−7.69, −4.19); P &lt; 0.000001</td>
</tr>
<tr>
<td>Qiang li ding xuan tablets</td>
<td>1</td>
<td>96</td>
<td>WMD: −9.40 (−13.32, −5.58); P &lt; 0.000001</td>
<td>WMD: −9.30 (−11.61, −6.99); P &lt; 0.000001</td>
</tr>
<tr>
<td>Qiang gan jiang ya capsules</td>
<td>1</td>
<td>80</td>
<td>WMD: −9.70 (−11.15, −8.25); P &lt; 0.000001</td>
<td>WMD: −3.50 (−5.41, −1.59); P = 0.0003</td>
</tr>
<tr>
<td>Qiang xuan jiang ya tablets</td>
<td>1</td>
<td>61</td>
<td>WMD: −1.00 (−4.17, 2.17); P = 0.54</td>
<td>WMD: 1.00 (−1.93, 3.93); P = 0.50</td>
</tr>
<tr>
<td>Tian shu capsules</td>
<td>1</td>
<td>60</td>
<td>WMD: −5.87 (−9.20, −2.54); P &lt; 0.000001</td>
<td>WMD: −1.87 (−4.27, 0.53); P = 0.13</td>
</tr>
<tr>
<td>Cornu saigae tataricaceae capsules</td>
<td>1</td>
<td>60</td>
<td>WMD: −13.50 (−18.06, −8.94); P &lt; 0.000001</td>
<td>WMD: −11.25 (−14.98, −7.52); P &lt; 0.000001</td>
</tr>
</tbody>
</table>

DBP = diastolic blood pressure, No. = number, SBP = systolic blood pressure, TCPM = traditional Chinese patent medicine, TPAD = traditional Chinese patent medicine plus antihypertensive drugs, WMD = weighted mean difference.

methodologies. Only 10 trials reported methods for randomization. Allocation concealment was not mentioned in any of the trials. Therefore, the “alleged” trials may not actually represent real RCTs, which could weaken the strength of the clinical evidence and lead to a potential selection bias. No trials were double-blinded. Only 1 trial reported the binding of participants and personnel. Blinding of the outcome assessment was not mentioned. This would directly lead to performance and detection biases. Additionally, there was a lack of placebo control use. All trials included in the review used an “A + B versus B” design, in which patients with EH are randomized to receive treatment (A) combined with treatment (B) versus treatment (B) alone. This type of add-on design is quite popular in TCM studies in which TCM therapy is added to conventional therapy. Nevertheless, without a rigorous control for a placebo effect, this approach may exaggerate the effects of TCPM and is prone to generate false-positive results and significant systemic errors in the assessment of outcomes. We understood that such
bias is a common problem in all TCM studies. Perhaps certain physical features associated with TCPMs, such as aromas, colors, and appearances, limited clinical placebo use. Unfortunately, none of the RCTs utilized a placebo control in the trials. Only a few trials reported drop-outs or withdrawals. Most of the trials did not report details of the intention-to-treat analysis. No trials had a pre-trial estimation of sample size. Thus, whether a sample size met the requirements of a given trial remains unknown.

Second, publication bias is another major cause of bias that should also be considered. We have made efforts to avoid language and location biases; however, only trials conducted in China and published in Chinese could be included for further analysis after comprehensive searches. Therefore, we cannot completely rule out the potential publication bias.

Furthermore, other systematic reviews regarding CAM have encountered similar problems. Recently, through huge investments in scientific research and the economical exploitation of TCM, the Chinese government has undertaken enormous efforts to modernize TCM and aims to prove the efficacy of TCM according to international standards. However, in our review, only 1 of the 73 selected articles declared their sources of funding.

Overall, the results of the trials included in this systematic review are likely to be biased by many factors because of the poor methodological qualities of these studies. The reported beneficial effect of TCPM in lowering BP in hypertensive patients should be interpreted cautiously. Additionally, 2 TCPMs, Song ling xue mai kang capsules and Yang xue qing nao granules, had more studies and greater patient numbers (>1000 patients) and may be worthy of further research.

CONCLUSIONS

In summary, this systematic review provided the first limited piece of clinical evidence regarding the effectiveness of TCPMs as a complementary therapy in improving mortality, the progression to severe complications, AEs, BP, and QOL. According to the Oxford Center for Evidence-Based Medicine 2011 Levels of Evidence, the usage of TCPMs for EH was supported by evidence of class level III. However, because of the negative results on primary outcomes, insufficient clinical data, poor methodological quality, small sample sizes, limited numbers of each trial, and the high heterogeneity of the studies, the current evidence is insufficient to support a recommendation for wide TCPM use.

Therefore, future studies should overcome the limitations of the trials included in this systematic review. The following methodological issues should be cautiously addressed: adequate generation of allocation sequences and the concealment of allocation; appropriate methods of double-blinding (blinding of participants and personnel and blinding of outcome assessment); wider use of placebo controls; strict reporting regarding drop-outs and the use of intention-to-treat analysis; a specifically focus on mortality and cardiovascular events with long-term follow-up; and comprehensive reporting of the trials according to the recommendations of the CONSORT Statement.

We also suggest that Song ling xue mai kang capsules and Yang xue qing nao granules, which were evaluated to be with the evidence of class level III, should be prioritized for further research. We hope that this systematic review will pave the way for the generation of evidence-based TCPMs for the treatment of EH.

ACKNOWLEDGMENTS

None.

REFERENCES


44. Xu LR, Gao XW, Chen JX. Effect of song ling xue mai kang capsule on 34 cases of elderly patients with hypertension of liver yang hyperactivity syndrome. Fujian J Tradit Chin Med. 2010;41:45.


